A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Exclusion Criteria

• •Candidate for potentially curative therapies in the opinion of the investigator.
• •Previous treatment with a PI3K inhibitor or Bruton's tyrosine kinase inhibitor.
• •Prior history of allogeneic hematopoietic stem cell transplant.
• •Prior chemotherapy, cancer immunosuppressive therapy, or other investigational agents within 4 weeks before first dose of study drug.
• •Grade 3B FL and/or clinical evidence of transformation to a more aggressive subtype of lymphoma.
• •Symptomatic central nervous system NHL.
• •Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment.
• •Prior, current, or chronic hepatitis B or hepatitis C infection, positive result for hepatitis C virus antibodies, hepatitis B surface antigen, or hepatitis B core antibodies.
• •History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to first dose of study drug.